The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
Collaboration supports multiple discovery efforts, including vaccines
The company has reported total income of Rs. 70.59 crores during the period ended June 30, 2022.
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
The company has reported total income of Rs. 129.96 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
